Search research articles
Contact Us
Filters
Showing results (101-110 of 209) with videos related to
Page
of 21
Sort By:
Clinical Genitourinary Cancer
|
May 7, 2016
Clinical Evaluation of Cisplatin Sensitivity of Germline Polymorphisms in Neoadjuvant Chemotherapy for Urothelial Cancer
Peter H O'Donnell, Shaheen Alanee, Kelly L Stratton, et al.
European Urology Oncology
|
April 17, 2025
Genetic Drivers of Quality of Life in Prostate Cancer: An Evaluation of Genetic Polymorphisms and Patient-reported Outcomes in the E3805 CHAARTED trial
Daniel Sentana-Lledo, Xiangying Chu, Charles J Ryan, et al.
Clinical Genitourinary Cancer
|
July 16, 2023
Results From a Randomized Phase II Trial of Sunitinib and Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma with Sarcomatoid Features: ECOG-ACRIN E1808
Bradley C Carthon, Se Eun Kim, David F McDermott, et al.
European Urology
|
January 4, 2022
Molecular Genetic Determinants of Shorter Time on Active Surveillance in a Prospective Phase 2 Clinical Trial in Metastatic Renal Cell Carcinoma
Oscar Reig Torras, Akhilesh Mishra, Alana Christie, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 20, 2020
Long-Term Outcomes in KEYNOTE-052: Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer
Jacqueline Vuky, Arjun V Balar, Daniel Castellano, et al.
BJU International
|
March 29, 2021
Safety of neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer and malignant ureteric obstruction
Marshall C Strother, Alexander Kutikov, Matthew Epstein, et al.
The Prostate
|
May 10, 2022
Association between baseline body mass index and survival in men with metastatic hormone-sensitive prostate cancer: ECOG-ACRIN CHAARTED E3805
Alicia K Morgans, Yu-Hui Chen, David F Jarrard, et al.
The Journal of Urology
|
March 28, 2015
A Phase II Study of Pazopanib in Patients with Localized Renal Cell Carcinoma to Optimize Preservation of Renal Parenchyma
Brian I Rini, Elizabeth R Plimack, Toshio Takagi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 21, 2017
Seven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With or Without Docetaxel
Lauren C Harshman, Yu-Hui Chen, Glenn Liu, et al.
Journal for Immunotherapy of Cancer
|
July 16, 2021
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancer
Matthew D Galsky, Arjun V Balar, Peter C Black, et al.
Page
of 21
Search research articles
Search
Showing results (101-110 of 209) with videos related to
Sort By:
Page
of 21
Clinical Genitourinary Cancer
|
May 7, 2016
Clinical Evaluation of Cisplatin Sensitivity of Germline Polymorphisms in Neoadjuvant Chemotherapy for Urothelial Cancer
Peter H O'Donnell, Shaheen Alanee, Kelly L Stratton, et al.
European Urology Oncology
|
April 17, 2025
Genetic Drivers of Quality of Life in Prostate Cancer: An Evaluation of Genetic Polymorphisms and Patient-reported Outcomes in the E3805 CHAARTED trial
Daniel Sentana-Lledo, Xiangying Chu, Charles J Ryan, et al.
Clinical Genitourinary Cancer
|
July 16, 2023
Results From a Randomized Phase II Trial of Sunitinib and Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma with Sarcomatoid Features: ECOG-ACRIN E1808
Bradley C Carthon, Se Eun Kim, David F McDermott, et al.
European Urology
|
January 4, 2022
Molecular Genetic Determinants of Shorter Time on Active Surveillance in a Prospective Phase 2 Clinical Trial in Metastatic Renal Cell Carcinoma
Oscar Reig Torras, Akhilesh Mishra, Alana Christie, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 20, 2020
Long-Term Outcomes in KEYNOTE-052: Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer
Jacqueline Vuky, Arjun V Balar, Daniel Castellano, et al.
BJU International
|
March 29, 2021
Safety of neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer and malignant ureteric obstruction
Marshall C Strother, Alexander Kutikov, Matthew Epstein, et al.
The Prostate
|
May 10, 2022
Association between baseline body mass index and survival in men with metastatic hormone-sensitive prostate cancer: ECOG-ACRIN CHAARTED E3805
Alicia K Morgans, Yu-Hui Chen, David F Jarrard, et al.
The Journal of Urology
|
March 28, 2015
A Phase II Study of Pazopanib in Patients with Localized Renal Cell Carcinoma to Optimize Preservation of Renal Parenchyma
Brian I Rini, Elizabeth R Plimack, Toshio Takagi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 21, 2017
Seven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With or Without Docetaxel
Lauren C Harshman, Yu-Hui Chen, Glenn Liu, et al.
Journal for Immunotherapy of Cancer
|
July 16, 2021
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancer
Matthew D Galsky, Arjun V Balar, Peter C Black, et al.
Page
of 21